Clear cell carcinoma of the endometrium.
Bogani G, Ray-Coquard I, Concin N, Ngoi NYL, Morice P, Enomoto T, Takehara K, Denys H, Lorusso D, Coleman R, Vaughan MM, Takano M, Provencher D, Sagae S, Wimberger P, Póka R, Segev Y, Kim SI, Kim JW, Candido Dos Reis FJ, Mariani A, Leitao MM Jr, Makker V, Rustum NA, Vergote I, Zannoni GF, Tan DSP, McCormack M, Bini M, Lopez S, Raspagliesi F, Panici PB, di Donato V, Muzii L, Colombo N, Scambia G, Pignata S, Monk BJ.
Gynecol Oncol. 2022 Mar;164(3):658-666. doi: 10.1016/j.ygyno.2022.01.012. Epub 2022 Jan 19.
Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology.
Abu-Rustum N, Yashar C, Arend R, Barber E, Bradley K, Brooks R, Campos SM, Chino J, Chon HS, Chu C, Crispens MA, Damast S, Fisher CM, Frederick P, Gaffney DK, Giuntoli R, Han E, Holmes J, Howitt BE, Lea J, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Podoll M, Salani R, Schorge J, Siedel J, Sisodia R, Soliman P, Ueda S, Urban R, Wethington SL, Wyse E, Zanotti K, McMillian NR, Aggarwal S.
J Natl Compr Canc Netw. 2023 Feb;21(2):181-209. doi: 10.6004/jnccn.2023.0006.
FIGO staging of endometrial cancer: 2023.
Berek JS, Matias-Guiu X, Creutzberg C, Fotopoulou C, Gaffney D, Kehoe S, Lindemann K, Mutch D, Concin N; Endometrial Cancer Staging Subcommittee, FIGO Women's Cancer Committee.
J Gynecol Oncol. 2023 Sep;34(5):e85. doi: 10.3802/jgo.2023.34.e85. Epub 2023 Aug 8.
Clear cell carcinoma of the endometrium: a biological and clinical enigma.
Gadducci A, Cosio S, Spirito N, Cionini L.
Anticancer Res. 2010 Apr;30(4):1327-34.
Prognostic factors in clear cell carcinoma of endometrium: analysis of 55 cases.
Loizzi V, Cicinelli E, Lepera A, Legge F, Memmola M, Chiarello G, Arezzo F, Del Vecchio V, Resta L, Cormio G.
Acta Biomed. 2022 Jan 19;92(6):e2021362. doi: 10.23750/abm.v92i6.11336.
Cell State of Origin Impacts Development of Distinct Endometriosis-Related Ovarian Carcinoma Histotypes.
Beddows I, Fan H, Heinze K, Johnson BK, Leonova A, Senz J, Djirackor S, Cho KR, Pearce CL, Huntsman DG, Anglesio MS, Shen H.
Cancer Res. 2024 Jan 2;84(1):26-38. doi: 10.1158/0008-5472.CAN-23-1362.
Clear Cell Carcinoma of the Endometrium: Evaluation of Prognostic Parameters in 27 Cases.
Zhang Z, Gao P, Bao Z, Zeng L, Yao J, Chai D, Li T.
Front Oncol. 2021 Dec 2;11:732782. doi: 10.3389/fonc.2021.732782. eCollection 2021.
A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
O'Cearbhaill RE, Miller A, Soslow RA, Lankes HA, DeLair D, Segura S, Chavan S, Zamarin D, DeBernardo R, Moore K, Moroney J, Shahin M, Thaker PH, Wahner-Hendrickson AE, Aghajanian C.
Gynecol Oncol. 2023 Sep;176:16-24. doi: 10.1016/j.ygyno.2023.06.021. Epub 2023 Jul 5.
Pure and mixed clear cell carcinoma of the endometrium: A molecular and immunohistochemical analysis study.
Reijnen C, Vrede SW, Eijkelenboom A, Draak R, Sweegers S, Snijders MPLM, van Gestel P, Pijnenborg JMA, Bulten J, Küsters-Vandevelde HVN.
Cancer Med. 2023 Jun;12(11):12365-12376. doi: 10.1002/cam4.5937. Epub 2023 Apr 20.
Molecular subtypes of clear cell carcinoma of the endometrium: Opportunities for prognostic and predictive stratification.
Kim SR, Cloutier BT, Leung S, Cochrane D, Britton H, Pina A, Storness-Bliss C, Farnell D, Huang L, Shum K, Lum A, Senz J, Lee CH, Gilks CB, Hoang L, McAlpine JN.
Gynecol Oncol. 2020 Jul;158(1):3-11. doi: 10.1016/j.ygyno.2020.04.043. Epub 2020 Apr 21.
